BioCartilage / Scaffolds / AMIC

What It Is

→ BioCartilage and AMIC add a "helper layer" on top of microfracture. A scaffold (like a cartilage-protein sponge) gives healing cells a structure to grow on. Like providing scaffolding for construction workers instead of building in mid-air.

BioCartilage is dehydrated, micronized allogeneic cartilage containing extracellular matrix (type II collagen, proteoglycans, cartilaginous growth factors). It acts as a scaffold over microfractured defects [29].

→ Allogeneic = from a donor (not your own tissue); extracellular matrix = the "glue" between cells; proteoglycans = cushioning molecules in cartilage

Systematic Review Outcomes

AMIC 2024 Systematic Review and Meta-Analysis

A June 2024 systematic review of 15 studies (12 case series for meta-analysis) [31]:

→ AMIC = Autologous Matrix-Induced Chondrogenesis; combines microfracture with a collagen membrane

• VAS, AOFAS ankle-hindfoot, and Tegner scores at last follow-up showed statistically significant improvement (p<0.001)
  → Tegner score = activity level scale (0-10); higher = more active lifestyle
• VAS improved 4.45-4.6 points from baseline at 1-5 year follow-up

AMIC 10-Year Cohort Study (2025)

A 2025 study in Cartilage evaluated 10-year outcomes [73]:

• "Gold standard surgical treatment for OCLs of the talus still needs to be established"
• AMIC is a commonly applied 1-stage procedure with good short/mid-term results
  → 1-stage = done in a single surgery (vs 2-stage which requires harvesting cells, growing them, then implanting)
• 10-year cohort tracked FFI-D scores preop and at 1, 5, and 10 years
  → FFI-D = Foot Function Index (German version); measures pain and disability

Arthroscopic AMIC 5-Year Follow-Up (2026 CARTILAGE)

Efrima et al. evaluated arthroscopic AMIC at 24 and 60 months [74]:

• Significant clinical improvement maintained at 5 years; improvement peaks in first 2 years then plateaus
• Patients older than 33 had significantly worse outcomes
• Increased age and BMI associated with inferior results
• Arthroscopic approach shows promise for reduced morbidity

DGOU 2024: Scaffold Sizing Guidance

The German cartilage society guidelines now offer clear sizing thresholds [128]:

• BMS alone: only for lesions <1.0 cm² without bony defect
• Scaffold augmentation recommended for lesions >1.0 cm² and for cystic defects
• Warning: bone grafting alone has a 46% revision rate — scaffolds improve this significantly
• Arthroscopy has technical limits for radical debridement of extended cystic lesions

2024 EMCA/BioCartilage Systematic Review

A 2024 systematic review of 162 ankles across 5 studies found [29]:

• Subjective improvement and some MRI advantages over BMS alone
• However, no consensus on EMCA's precise role — longer comparative studies needed

Concerns

• High reoperation rate: 54.6% underwent subsequent surgery (mostly hardware removal) [33]
• Only 14% of revisions were graft-related complications [33]
• MaioRegen scaffold: 31% failure rate (5/16), 4 required prostheses [34]

For revision cases: This branch looks strongest when the surgeon treats it as a lower-morbidity bridge or bone-restoring/staging step, not as a definitive standalone answer for failed grafts.

Added August 3, 2026 — Arthrex is running a talus-specific BioCartilage study, and its complication profile is nerve-and-wound heavy

→ Found in the FDA's adverse-event database rather than in the literature. It means results for this exact use are coming, and it is the first look at what goes wrong.

A safety filing quotes its own source: “Information had been obtained from a clinical study, a pilot study to evaluate the efficacy of BioCartilage micronized cartilage matrix in microfracture treatment of osteochondral defects of the talus (US-01096)” [324]. Reported events include plantar-nerve involvement and possible tarsal tunnel syndrome, bilateral neurological changes, an infected suture, a 40° gastrocnemius contracture, and “a total of four (4) reoperations.” All were assessed by the manufacturer as unrelated to the device.

Read it for what it is. This is an aggregated manufacturer safety filing, not a results publication — there are no outcome scores, no denominator, and no way to know how many patients were enrolled. It does not say the technique failed. Two things follow that are worth carrying: a named talus-specific trial exists and its results should eventually publish, and the complications clustered around nerves and wound healing rather than around the graft, which is a question worth asking any surgeon proposing this approach. For a 15 × 10 mm cystic revision lesion, BioCartilage over microfracture remains a weaker option than autograft, allograft or cell therapy regardless.